| US 7,514,442 B2 | ||
| Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors | ||
| Timothy J. Guzi, Chatham, N.J. (US); Kamil Paruch, Garwood, N.J. (US); Michael P. Dwyer, Scotch Plains, N.J. (US); Ronald J. Doll, Convent Station, N.J. (US); Viyyoor M. Girijavallabhan, Parsippany, N.J. (US); Carmen S. Alvarez, Livingston, N.J. (US); Tin Yau Chan, Edison, N.J. (US); Chad Knutson, Garwood, N.J. (US); Vincent Madison, Mountain Lakes, N.J. (US); Thierry O. Fischmann, Scotch Plains, N.J. (US); Lawrence W. Dillard, Skillman, N.J. (US); Vinh D. Tran, Fountain Valle, Calif. (US); Zhen Min He, Princeton, N.J. (US); Ray Anthony James, Bensalem, Pa. (US); and Haengsoon Park, Plainsboro, N.J. (US) | ||
| Assigned to Schering Corporation, Kenilworth, N.J. (US); and Pharmacopeia, Inc., Cranbury, N.J. (US) | ||
| Filed on Mar. 31, 2006, as Appl. No. 11/395,676. | ||
| Application 11/395676 is a division of application No. 10/653776, filed on Sep. 03, 2003, granted, now 7,067,661. | ||
| Claims priority of provisional application 60/408029, filed on Sep. 04, 2002. | ||
| Prior Publication US 2006/0178371 A1, Aug. 10, 2006 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 31/519 (2006.01); C07D 487/04 (2006.01); A61P 35/04 (2006.01) | ||
| U.S. Cl. 514—259.3 [544/281; 514/263.32; 514/252.17; 514/183; 514/81; 514/110; 514/234.2; 514/252.16; 514/151; 514/8; 514/9; 514/27; 514/167; 514/15; 514/221; 514/245; 424/649; 424/94.4] | 12 Claims |
1. A method of treating chronic lymphocytic leukemia (CLL) by inhibiting a cyclin dependent kinase in a patient, comprising
administering a therapeutically effective amount of at least one compound represented by the structural formula I:
![]() R is an unsubstituted aryl or aryl substituted with one or more moieties which moieties can be the same or different, each
moiety being independently selected from the group consisting of halogen, CN, —OR5, SR5, —CH2OR5, —C(O)R5, —SO3H, —S(O)2R6, —S(O)2NR5R6, —NR5R6, —C(O)NR5R6, —CF3, —OCF3 and heterocyclyl;
R2 is selected from the group consisting of R9, alkyl(C2-C6), alkynyl, alkynylalkyl, cycloalkyl, —CF3, —C(O)2R6, aryl, arylalkyl, heteroarylalkyl, heterocyclyl, alkyl substituted with 1-6 R9 groups which groups can be the same or different with each R9 being independently selected, aryl substituted with 1-3 aryl or heteroaryl groups which can be the same or different and are
independently selected from phenyl, pyridyl, thiophenyl, furanyl and thiazolo groups,
![]() R3 is selected from the group consisting of H, halogen, —NR5R6, —C(O)NR5R6 alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl and heteroarylalkyl,
![]() wherein each of said alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl and heteroarylalkyl for R3 and the heterocyclyl moieties whose structures are shown immediately above for R3 can be substituted or optionally independently substituted with one or more moieties which can be the same or different, each
moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF3, CN, —OCF3, —(CR4R5)nOR5, —OR5, —NR5R6 , —(CR4R5)nNR5R6, —C(O)2R5, —C(O)R5, —C(O)NR5R6, —SR6, —S(O)2R6, —S(O)2NR5R6, —N(R5)S(O)2R7, —N(R5)C(O)7 and —N(R5)C(O)NR5R6;
R4 is H, halo or alkyl;
R5 is H or alkyl;
R6 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl,
wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl can be unsubstituted
or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected
from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF3, OCF3, CN, —OR5, —NR5R10, —N(R5) (tertiarybutoxycarbonyl), —(CR4R5)nOR5, —C(O)2alkyl(C2-C6), —C(O)R5, —C(O)NR5R10, —SO3H, —SR10, —S(O)2R7, —S(O)2NR5R10, —N(R5)S(O)2R7, —N(R5)C(O)R7 and —N(R5)C(O)NR5R10 with the proviso that said arylalkyl is not substituted by the —C(O)2alkyl(C2-C6);
R10 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl,
wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl can be unsubstituted
or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected
from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF3, OCF3, CN, —OR5, —NR4R5, —N(R5) (tertiarybutoxycarbonyl), —(OR4R5)nOR5, —C(O)2R5, —C(O)N R4R5, —C(O)R5, —SO3H, —SR5, —S(O)2R7, —S(O)2NR4R5, —N(R5)S(O)2R7, —N(R5)C(O)R7 and —N(R5)C(O)NR4R5;
or optionally (i) R5 and R10 in the moiety —NR5R10, or (ii) R5 and R6 in the moiety —NR5R6, may be joined together to form a heterocyclyl moiety, with each of said heterocyclyl moiety being unsubstituted or optionally
independently being substituted with one or more R9 groups;
R7 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each
of said alkyl, cycloalkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally independently
substituted with one or more moieties which can be the same or different, each moiety being independently selected from the
group consisting of halogen, alkyl, aryl, cycloalkyl, CF3, OCF3, CN, —OR5, —NR5R10, —CH2OR5, —C(O)2R5, —C(O)NR5R10, —C(O)R5, —SR10, —S(O)2R10, —S(O)2NR5R10, —N(R5)S(O)2R10, —N(R5)C(O)R10 and —N(R5)C(O)NR5R10;
R8 is selected from the group consisting of R6, —C(O)NR5R10, —S(O)2NR5R10, —C(O)R7and —S(O)2R7;
R9 is selected from the group consisting of halogen, CN, —NR5R10, —C(O)2R6, —C(O)NR5R10, —OR6, —SR6, —S(O)2R7, —S(O)2NR5R10, —N(R5)S(O)2R7, —N(R5)C(O)R7and —N(R5)C(O)NR5R10;
m is 0 to 4, and
n is 1 to 4, with the following provisos: (i) that when N is an unsubstituted phenyl, then R2 is not alkyl(C2-C6), —C(O)2R6, aryl or cycloalkyl, and (ii) that when R is a phenyl substituted with a hydroxyl group, then R2 is halogen only, or a pharmaceutically acceptable salt thereof, to said patient, wherein said cyclin dependent kinase is CDK1
or CDK2.
|